All In Biotech

Drug Trial Radar · NCT04068896

Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy

A Phase 1/2 Dose-Finding Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy

Last checked: Nov 19, 2026Latest source record: May 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

89

Actual

Start

Oct 16, 2019

Primary completion

Sep 21, 2023

Study completion Jan 8, 2024

Sponsor

Lead sponsor
NGM Biopharmaceuticals, IncIndustry
Sponsor type
Industry
First posted
Aug 28, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study of NGM120 in subjects with advanced solid tumors and pancreatic cancer (Part 1 and 2) and metastatic castration resistant prostate cancer (Part 3).

Conditions

  • Pancreatic Cancer
  • Metastatic Castration-resistant Prostate Cancer
  • Bladder Cancer
  • Melanoma
  • Non-small Cell Lung Cancer
  • Colorectal Cancer
  • Gastric Cancer
  • Esophageal Cancer
  • Ovarian Cancer
  • Head Neck Squamous Cell Carcinoma
  • Prostate Cancer

Interventions

  • NGM120 30mgBiological

    NGM120 30mg Subcutaneous Injection

  • NGM120 100mgBiological

    NGM120 100mg Subcutaneous Injection

  • NGM120 30mg with Gemcitabine and AbraxaneBiological

    NGM120 30mg Subcutaneous Injection together with gemcitabine (1000 mg/m2 weekly for first 3 weeks of the 4-week cycle) and Abraxane (125 mg/m2 weekly for first 3 weeks of the 4-week cycle).

  • NGM120 100mg with Gemcitabine and AbraxaneBiological

    NGM120 100 mg Subcutaneous Injection together with gemcitabine (1000 mg/m2 weekly for first 3 weeks of the 4-week cycle) and Abraxane (125 mg/m2 weekly for first 3 weeks of the 4-week cycle).

  • NGM120 100mg Q3WBiological

    NGM120 100mg Subcutaneous Injection every 3 weeks

  • PlaceboOther

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To Determine the Safety and Tolerability of NGM120 in SubjectsTime frame: From enrollment to end of treatment up to 24 months
  2. To Determine the Safety and Tolerability of NGM120Time frame: From enrollment to end of treatment up to 24 months
  3. To Determine the Safety and Tolerability of NGM120Time frame: From enrollment to end of treatment up to 24 months

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • NGM Clinical Study Site

    Tucson, Arizona

  • NGM Clinical Study Site

    Los Angeles, California

  • NGM Clinical Study Site

    Los Angeles, California

  • NGM Clinical Study Site

    Sacramento, California

  • NGM Clinical Study Site

    San Diego, California

  • NGM Clinical Study Site

    Santa Monica, California

  • NGM Clinical Study Site

    Aurora, Colorado

  • NGM Clinical Study Site

    Washington D.C., District of Columbia

  • NGM Clinical Study Site

    Miami, Florida

  • NGM Clinical Study Site

    Chicago, Illinois

  • NGM Clinical Study Site

    Baltimore, Maryland

  • NGM Clinical Study Site

    Cincinnati, Ohio

  • NGM Clinical Study Site

    Philadelphia, Pennsylvania

  • NGM Clinical Study Site

    Charleston, South Carolina

  • NGM Clinical Study Site

    Myrtle Beach, South Carolina

  • NGM Clinical Study Site

    Nashville, Tennessee

  • NGM Clinical Study Site

    Dallas, Texas

  • NGM Clinical Study Site

    Houston, Texas

  • NGM Clinical Study Site

    Seattle, Washington

  • NGM Clinical Study Site

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.